Viartis

Viatris is a global healthcare company formed in 2020 through the combination of Mylan and Pfizer's Upjohn business. The company provides a broad portfolio of medicines, including iconic brands, generic and complex generic medicines, and a growing range of biosimilars. Viatris focuses on multiple therapeutic areas such as cardiovascular, oncology, immunology, and more recently, ophthalmology following strategic acquisitions of Oyster Point Pharma and Famy Life Sciences. The company operates an extensive global manufacturing and supply chain network, serving patients in more than 165 countries and territories. Viatris is committed to expanding access to high-quality medicines and addressing unmet medical needs through its diverse product pipeline.